Outcomes after anti-thymocyte globulin vs Basiliximab induction before deceased donor kidney transplants

Hafeez, Muhammad Saad; Haq, Muneeb Ul; Bakhthiyar, Syed Shahyan; Azhar, Kumael; Awan, Ahmad; Murthy, Β. V. R.; Abbas, Rana Zamin

doi:10.1016/j.trim.2022.101733

Cited by 1 publication

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most suitable antibodies recognise the markers CD2, CD3, CD4, CD8, CD11a, CD18, CD25, CD28, CD40 and CD54 and have a broad immunosuppressive spectrum compared to monoclonal antibodies [ 25 ]. Hafeez et al [ 26 ] examined the anti-thymocyte globulin aspect of induction to deceased donor kidney transplants. The authors indicated favourable rejection, patient survival and graft survival with anti-thymocyte globulin usage [ 26 ].…”

Section: Classes Of Immunosuppressive Drugsmentioning

confidence: 99%

“…Hafeez et al [ 26 ] examined the anti-thymocyte globulin aspect of induction to deceased donor kidney transplants. The authors indicated favourable rejection, patient survival and graft survival with anti-thymocyte globulin usage [ 26 ]. It should be added that Muromonab-CD3, often referred to as OKT3, was previously used to treat acute cellular rejection after solid organ transplantation.…”

Section: Classes Of Immunosuppressive Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation

Szumilas

Wilk

Wiśniewski

et al. 2023

IJMS

View full text Add to dashboard Cite

Renal transplantation is now the best treatment for end-stage renal failure. To avoid rejection and prolong graft function, organ recipients need immunosuppressive therapy. The immunosuppressive drugs used depends on many factors, including time since transplantation (induction or maintenance), aetiology of the disease, and/or condition of the graft. Immunosuppressive treatment needs to be personalised, and hospitals and clinics have differing protocols and preparations depending on experience. Renal transplant recipient maintenance treatment is mostly based on triple-drug therapy containing calcineurin inhibitors, corticosteroids, and antiproliferative drugs. In addition to the desired effect, the use of immunosuppressive drugs carries risks of certain side effects. Therefore, new immunosuppressive drugs and immunosuppressive protocols are being sought that exert fewer side effects, which could maximise efficacy and reduce toxicity and, in this way, reduce both morbidity and mortality, as well as increase opportunities to modify individual immunosuppression for renal recipients of all ages. The aim of the current review is to describe the classes of immunosuppressive drugs and their mode of action, which are divided by induction and maintenance treatment. An additional aspect of the current review is a description of immune system activity modulation by the drugs used in renal transplant recipients. Complications associated with the use of immunosuppressive drugs and other immunosuppressive treatment options used in kidney transplant recipients have also been described.

show abstract

Section: Classes Of Immunosuppressive Drugsmentioning

confidence: 99%

Section: Classes Of Immunosuppressive Drugsmentioning

confidence: 99%